About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

370533 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
 Menu
This website is for US healthcare professionals
close-icon

Log In to Bolder Science

logo-iconLog in with Doximity
or
Forgot Password

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

logo-iconLog in with Doximity
or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Specialties

Choose 1 or more specialties that you are interested in:

Subspecialties

You can specify a subspecialty for areas you selected (if available):

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
Previous Next skip
Our Science

    • pomalidomide (IMiD® Agent)

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

    Proposed Mechanism of Action

    Pomalidomide is an oral immunomodulatory agent that, as demonstrated in vitro, inhibits proliferation and induces apoptosis of tumor cells, and inhibits proliferation of lenalidomide-resistant myeloma cells.1-3

    In preclinical studies, pomalidomide has demonstrated direct tumoricidal and immunomodulatory effects, which are mediated in both myeloma and immune cells by co-opting cereblon, a component of the E3 ubiquitin ligase complex.1-5 This redirection triggers proteasomal degradation of the transcription factors Ikaros and Aiolos,3,5,6 resulting in downregulation of the myeloma survival signals IRF4 and c-Myc and upregulation of the immunoregulatory molecule IL-2.1,5,6 Additionally, pomalidomide may have inhibitory effects on stromal-cell support in the bone marrow microenvironment, including inhibition of soluble protein production that supports myeloma cell growth and angiogenesis4,7

    Pomalidomide Hypothesized Mechanism of Action

    Pomalidomide is an IMiD agent hypothesized to have tumoricidal and immunomodulatory effects in multiple myeloma.

    pomalidomide by Disease State

    pomalidomide in Multiple Myeloma

    Post Approval Research
    Relapsed/refractory

    View Trials Investigating pomalidomide in Multiple Myeloma
    View Rationale for Clinical Development

    Rationale for Clinical Development

    For patients with multiple myeloma (MM) who are refractory to agents including bortezomib and lenalidomide, the prognosis is poor.8,9 Pomalidomide has demonstrated inhibition of myeloma cell proliferation, induction of myeloma cell apoptosis, and immunomodulatory effects in preclinical studies, including in lenalidomide-resistant myeloma cells.1-5 Additionally, pomalidomide has shown increased anti-myeloma activity in combination with dexamethasone and bortezomib in vitro.2,3

    Pomalidomide Title

    Pomalidomide Desc

    Download

    View Related Pathways

    Cereblon/E3 Ligase Pathway
    Cereblon E3 Ligase Modulation (CELMoD® Agents) in Targeted Protein Degradation

    References

    1. Lopez-Girona A, et al. Leukemia. 2012;26:2326-2335. PMID: 22552008
    2. Rychak E, et al. Br J Haematol. 2016;172:889-901. PMID: 26914976
    3. Katz M, et al. Poster presented at: American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego, CA [abstract 1934].
    4. Quach H, et al. Leukemia. 2010;24:22-32. PMID: 19907437
    5. Gandhi AK, et al. Br J Haematol. 2014;164:811-821. PMID: 24328678
    6. Bjorklund CC, et al. Blood Cancer J. 2015;5:e354. PMID: 26430725
    7. Gupta D, et al. Leukemia. 2001;15:1950-1961. PMID: 11753617
    8. Kumar SK, et al. Leukemia. 2012;26:149-157. PMID: 21799510
    9. Kumar SK, et al. Leukemia. 2017;31:2443-2448. PMID: 28620163